GlassScriptPhysician profile
Nakyoung Nam
NPI 1518167436
$6,638.68
in general payments reported to CMS, 2019-2025
32 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $554 · 2021: $635 · 2022: $655 · 2023: $902 · 2024: $1,038 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.10 |
| Education | $114.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $911.49 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $887.41 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $699.10 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $598.25 | 2019-2025 | Dupixent |
| Genzyme Corporation | $485.39 | 2019-2025 | |
| Csl Behring | $373.22 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Novartis Pharmaceuticals Corporation | $355.41 | 2019-2025 | |
| Pfizer INC. | $324.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.88 | 2020-2025 | Cuvitru, Takhzyro |
| Kaleo, INC. | $271.11 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $262.07 | 2019-2025 | |
| Covis Pharma Gmbh | $200.17 | 2019-2022 | |
| Grifols USA, LLC | $91.79 | 2019-2024 | Xembify |
| Abbvie INC. | $90.71 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $80.07 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $78.27 | 2020 | |
| Genentech USA, INC. | $66.53 | 2022 | |
| Pharming Healthcare, INC. | $65.38 | 2022-2025 | Ruconest |
| Shire North American Group INC | $65.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.71 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Azurity Pharmaceuticals, INC. | $52.91 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $46.89 | 2025 | Ryaltris |
| Biocryst US Sales Co., LLC | $45.60 | 2024-2025 | Orladeyo |
| Aimmune Therapeutics, INC. | $44.34 | 2022 | |
| Alk-Abello, INC | $39.90 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Lilly USA, LLC | $22.65 | 2025 | Ebglyss |
| Dermavant Sciences, INC. | $19.67 | 2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $17.58 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $17.21 | 2023 | |
| Galderma Laboratories, L.P. | $17.03 | 2025 | Nemluvio |
| Organon LLC | $15.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakyoung Nam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.